MGF-E peptide in primary human muscle progenitor cells
The study reported increased proliferation/fusion-related activity in some donor-age groups.
What this study tells us
This was laboratory or cell research, not a human treatment trial. It can help explain a mechanism, but it cannot prove clinical benefit or safety in people.
Primary human muscle progenitor cells
No participant count — this was laboratory or analytical research.
The study reported increased proliferation/fusion-related activity in some donor-age groups.
The tested peptide was MGF-E, not necessarily the commercial PEG-MGF product; in-vitro findings cannot establish muscle-building efficacy in humans.
Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →
Key result
The study reported increased proliferation/fusion-related activity in some donor-age groups.